These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 32472047)

  • 21. Association of tear matrix metalloproteinase 9 immunoassay with signs and symptoms of dry eye disease: A cross-sectional study using qualitative, semiquantitative, and quantitative strategies.
    Lee YH; Bang SP; Shim KY; Son MJ; Kim H; Jun JH
    PLoS One; 2021; 16(10):e0258203. PubMed ID: 34662364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of matrix metallopeptidase-9 expression following cyclosporine and diquafosol treatment in dry eye.
    So HR; Baek J; Lee JY; Kim HS; Kim MS; Kim EC
    Ann Med; 2023 Dec; 55(1):2228192. PubMed ID: 37354028
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ocular surface disease and glaucoma: how to evaluate impact on quality of life.
    Rossi GC; Pasinetti GM; Scudeller L; Bianchi PE
    J Ocul Pharmacol Ther; 2013 May; 29(4):390-4. PubMed ID: 23215770
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tear film osmolarity in patients treated for glaucoma or ocular hypertension.
    Labbé A; Terry O; Brasnu E; Van Went C; Baudouin C
    Cornea; 2012 Sep; 31(9):994-9. PubMed ID: 22710490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of topical cyclosporine 0.05% and osmoprotective lubricating eye drops in treating dry eye disease and inflammation.
    Mullick R; Annavajjhala S; Thakur P; Mohapatra A; Shetty R; D'Souza S
    Indian J Ophthalmol; 2021 Dec; 69(12):3473-3477. PubMed ID: 34826977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of Ocular Surface Disease Treatment in Patients with Glaucoma.
    Mylla Boso AL; Gasperi E; Fernandes L; Costa VP; Alves M
    Clin Ophthalmol; 2020; 14():103-111. PubMed ID: 32021074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of Ocular Surface Disease in Glaucoma Patients in Ghana.
    Kobia-Acquah E; Gyekye GA; Antwi-Adjei EK; Koomson NY; Cobbina F; Donkor R; Akowuah PK
    J Glaucoma; 2021 Feb; 30(2):180-186. PubMed ID: 33074962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of artificial tears on automated visual field testing in patients with glaucoma and dry eye.
    Kocabeyoglu S; Mocan MC; Bozkurt B; Irkec M
    Can J Ophthalmol; 2013 Apr; 48(2):110-4. PubMed ID: 23561604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of ocular surface disease on optical coherence tomography test results in patients with glaucoma.
    Oktay Ö; Dursun Ö; Yılmaz A
    Eur J Ophthalmol; 2021 Nov; 31(6):2997-3002. PubMed ID: 33506697
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased homocysteine levels in tear fluid of patients with primary open-angle glaucoma.
    Roedl JB; Bleich S; Schlötzer-Schrehardt U; von Ahsen N; Kornhuber J; Naumann GO; Kruse FE; Jünemann AG
    Ophthalmic Res; 2008; 40(5):249-56. PubMed ID: 18437035
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel point-of-care biomarkers of the dry anophthalmic socket syndrome: tear film osmolarity and matrix metalloproteinase 9 immunoassay.
    Rokohl AC; Wall K; Trester M; Wawer Matos PA; Guo Y; Adler W; Pine KR; Heindl LM
    Graefes Arch Clin Exp Ophthalmol; 2023 Mar; 261(3):821-831. PubMed ID: 36357674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Ocular surface in glaucoma patients with topical treatment].
    Zemba M; Papadatu CA; Enache VE; Sârbu LN
    Oftalmologia; 2011; 55(3):94-8. PubMed ID: 22428298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ocular Surface Changes After Switching from Other Prostaglandins to Tafluprost and Preservative-Free Tafluprost in Glaucoma Patients.
    Ruangvaravate N; Choojun K; Srikulsasitorn B; Chokboonpiem J; Asanatong D; Trakanwitthayarak S
    Clin Ophthalmol; 2020; 14():3109-3119. PubMed ID: 33116362
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of topical low-dose preservative-free hydrocortisone on intraocular pressure in patients affected by ocular surface disease with and without glaucoma.
    Filippelli M; dell'Omo R; Gelso A; Rinaldi M; Bartollino S; Napolitano P; Russo A; Campagna G; Costagliola C
    Graefes Arch Clin Exp Ophthalmol; 2022 Jan; 260(1):247-253. PubMed ID: 34406502
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Functional Activity of Matrix Metalloproteinases 2 and 9 in Tears of Patients With Glaucoma.
    Sahay P; Rao A; Padhy D; Sarangi S; Das G; Reddy MM; Modak R
    Invest Ophthalmol Vis Sci; 2017 May; 58(6):BIO106-BIO113. PubMed ID: 28586796
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Topical 0.05% Cyclosporine A for Ocular Surface Disease Related to Topical Anti-Glaucoma Medications.
    Kim JG; An JH; Cho SY; Lee CE; Shim KY; Jun JH
    J Ocul Pharmacol Ther; 2023 Jul; 39(6):389-397. PubMed ID: 37267211
    [No Abstract]   [Full Text] [Related]  

  • 37. Determination of inmune response and inflammation mediators in tears: Changes in dry eye and glaucoma as compared to healthy controls.
    Benitez-Del-Castillo Sánchez J; Morillo-Rojas MD; Galbis-Estrada C; Pinazo-Duran MD
    Arch Soc Esp Oftalmol; 2017 May; 92(5):210-217. PubMed ID: 28169068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Exploring topical anti-glaucoma medication effects on the ocular surface in the context of the current understanding of dry eye.
    Wong ABC; Wang MTM; Liu K; Prime ZJ; Danesh-Meyer HV; Craig JP
    Ocul Surf; 2018 Jul; 16(3):289-293. PubMed ID: 29510226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tear Lipid Layer Thickness Change and Topical Anti-Glaucoma Medication Use.
    Lee SY; Lee H; Bae HW; Kim TI; Kim CY
    Optom Vis Sci; 2016 Oct; 93(10):1210-1217. PubMed ID: 27668491
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ocular Surface Disease in Glaucoma Patients Randomized to Benzalkonium Chloride-Containing Latanoprost and Preservative-Free Bimatoprost.
    Wu JH; Wang TH; Huang JY; Su CC
    J Ocul Pharmacol Ther; 2021 Dec; 37(10):556-564. PubMed ID: 34610257
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.